Adulteration of proprietary Chinese medicines and health products with undeclared drugs: experience of a tertiary toxicology laboratory in Hong Kong. (4th October 2017)
- Record Type:
- Journal Article
- Title:
- Adulteration of proprietary Chinese medicines and health products with undeclared drugs: experience of a tertiary toxicology laboratory in Hong Kong. (4th October 2017)
- Main Title:
- Adulteration of proprietary Chinese medicines and health products with undeclared drugs: experience of a tertiary toxicology laboratory in Hong Kong
- Authors:
- Ching, Chor Kwan
Chen, Sammy Pak Lam
Lee, Hencher Han Chih
Lam, Ying Hoo
Ng, Sau Wah
Chen, Mo Lung
Tang, Magdalene Huen Yin
Chan, Suzanne Suk San
Ng, Candy Wai Yan
Cheung, Jana Wing Lan
Chan, Tina Yee Ching
Lau, Nike Kwai Cheung
Chong, Yeow Kuan
Mak, Tony Wing Lai - Abstract:
- Abstract : Aims: Proprietary Chinese medicines (pCMs) and health products, generally believed to be natural and safe, are gaining popularity worldwide. However, the safety of pCMs and health products has been severely compromised by the practice of adulteration. The current study aimed to examine the problem of adulteration of pCMs and health products in Hong Kong. Methods: The present study was conducted in a tertiary referral clinical toxicology laboratory in Hong Kong. All cases involving the use of pCMs or health products, which were subsequently confirmed to contain undeclared adulterants, from 2005 to 2015 were reviewed retrospectively. Results: A total of 404 cases involving the use of 487 adulterated pCMs or health products with a total of 1234 adulterants were identified. The adulterants consisted of approved drugs, banned drugs, drug analogues and animal thyroid tissue. The six most common categories of adulterants detected were nonsteroidal anti‐inflammatory drugs (17.7%), anorectics (15.3%), corticosteroids (13.8%), diuretics and laxatives (11.4%), oral antidiabetic agents (10.0%) and erectile dysfunction drugs (6.0%). Sibutramine was the most common adulterant ( n = 155). The reported sources of these illicit products included over‐the‐counter drug stores, the internet and Chinese medicine practitioners . A significant proportion of patients (65.1%) had adverse effects attributable to these illicit products, including 14 severe and two fatal cases. Psychosis,Abstract : Aims: Proprietary Chinese medicines (pCMs) and health products, generally believed to be natural and safe, are gaining popularity worldwide. However, the safety of pCMs and health products has been severely compromised by the practice of adulteration. The current study aimed to examine the problem of adulteration of pCMs and health products in Hong Kong. Methods: The present study was conducted in a tertiary referral clinical toxicology laboratory in Hong Kong. All cases involving the use of pCMs or health products, which were subsequently confirmed to contain undeclared adulterants, from 2005 to 2015 were reviewed retrospectively. Results: A total of 404 cases involving the use of 487 adulterated pCMs or health products with a total of 1234 adulterants were identified. The adulterants consisted of approved drugs, banned drugs, drug analogues and animal thyroid tissue. The six most common categories of adulterants detected were nonsteroidal anti‐inflammatory drugs (17.7%), anorectics (15.3%), corticosteroids (13.8%), diuretics and laxatives (11.4%), oral antidiabetic agents (10.0%) and erectile dysfunction drugs (6.0%). Sibutramine was the most common adulterant ( n = 155). The reported sources of these illicit products included over‐the‐counter drug stores, the internet and Chinese medicine practitioners . A significant proportion of patients (65.1%) had adverse effects attributable to these illicit products, including 14 severe and two fatal cases. Psychosis, iatrogenic Cushing syndrome and hypoglycaemia were the three most frequently encountered adverse effects. Conclusions: Adulteration of pCMs and health products with undeclared drugs poses severe health hazards. Public education and effective regulatory measures are essential to address the problem. … (more)
- Is Part Of:
- British journal of clinical pharmacology. Volume 84:Number 1(2018:Jul.)
- Journal:
- British journal of clinical pharmacology
- Issue:
- Volume 84:Number 1(2018:Jul.)
- Issue Display:
- Volume 84, Issue 1 (2018)
- Year:
- 2018
- Volume:
- 84
- Issue:
- 1
- Issue Sort Value:
- 2018-0084-0001-0000
- Page Start:
- 172
- Page End:
- 178
- Publication Date:
- 2017-10-04
- Subjects:
- drug adulteration -- health products -- poisoning -- proprietary Chinese medicines
Pharmacology -- Periodicals
Drugs -- Periodicals
615.1 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2125 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/bcp.13420 ↗
- Languages:
- English
- ISSNs:
- 0306-5251
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2307.180000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 5550.xml